Navigation Links
Targeting downstream proteins in cancer-causing pathway shows promise in cell, animal model
Date:11/13/2012

PHILADELPHIA - The cancer-causing form of the gene Myc alters the metabolism of mitochondria, the cell's powerhouse, making it dependent on the amino acid glutamine for survival. In fact, 40 percent of all "hard-to-treat" cancers have a mutation in the Myc gene.

Accordingly, depriving cells of glutamine selectively induces programmed cell death in cells overexpressing mutant Myc.

Using Myc-active neuroblastoma cancer cells, a team led by Howard Hughes Medical Institute (HHMI) investigator M. Celeste Simon, Ph.D., scientific director for the Abramson Family Cancer Research Institute (AFCRI), identified the proteins PUMA, NOXA, and TRB3 as executors of the glutamine-starved cells. These three proteins represent a downstream target in the Myc pathway at which to aim drugs. Roughly 25 percent of all neuroblastoma cases are associated with Myc-active cells.

The findings appear in this week's issue of Cancer Cell. Simon is also a professor of Cell and Developmental Biology at the Perelman School of Medicine, University of Pennsylvania. The Penn team collaborated with colleagues from The Children's Hospital of Philadelphia (CHOP) John Maris and Michael Hogarty.

"These findings come from studies of fundamental cellular pathways and would not have been discovered without ongoing support for basic research," notes Simon. "Translational research is very important, but equal emphasis on basic research of processes such as cellular metabolism is critical for the ultimate cure of cancer."

Glutamine depletion in Myc-mutant cells induces cell death through a complicated series of molecular switches involving the three protein executors and the DNA-binding protein ATF4. Knowing this, the team showed that either agonists of ATF4 or inhibitors of glutamine metabolism potently caused cell death in assays using neuroblastoma cells and inhibited tumor growth in transgenic mice. Drugs in these two classes have been approved by the Food and Dru
'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Targeting inflammation to treat depression
2. Targeting inflammation to prevent, treat cancers
3. New targeting technology improves outcomes for patients with atrial fibrillation
4. IBN discovers human neural stem cells with tumor targeting ability
5. Scientists tailor cell surface targeting system to hit organelle ZIP codes
6. G proteins regulate remodelling of blood vessels
7. Salk study finds diabetes raises levels of proteins linked to Alzheimers features
8. Toward medicines that recruit the bodys natural disease-fighting proteins
9. Enzymes implicated in disease processes attack one another instead of harming body proteins
10. New regulatory mechanism discovered in cell system for eliminating unneeded proteins
11. Vanderbilt researchers find proteins may point way to new prostate cancer drug targets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... April 8th, 2015, saw the transformation of the ... Movie Awards” EcoLuxe Lounge, a daylong event, sponsored by ... world’s top providers of ecologically sound and social conscious ... Durkin, Los Angeles’ leading producer of sustainable product placement ... premier red carpet event that makes appearances at various ...
(Date:6/2/2015)... Angeles, CA (PRWEB) June 02, 2015 Highly ... have unveiled a plan to drive prolific change in the ... the TDC Team Dental Clinic offers a full ... an expert management structure for dental tourism. , Partnered with ... care team is committed to advancing dentistry and has earned ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 The 3TVPhoenix contest, ... to watch the station’s 6:00 a.m. Good Morning Arizona program ... on the station’s Facebook page. , Lisa Allen ... participants. She plans to apply the monthly $1,000 prize ... Allen, a stay-at-home mom, expressed her surprise and gratitude at ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 The Horizon ... announced today that its Walking and Wellness Challenge, held ... by Acer, has raised another $3,000 for the Boys ... undertook the challenge, recording 32,000 steps on her fitbit ... Seaview Hotel & Golf Club in Galloway Township. ...
(Date:6/2/2015)... Prussia, PA (PRWEB) June 02, 2015 ... Outsourcing solutions for health plans in the Medicare Advantage, ... participation as a sponsor and exhibitor at AHIP’s Institute ... America’s Health Insurance Plans. The conference will be held ... exhibition booth, #1303, will offer opportunities for attendees to ...
Breaking Medicine News(10 mins):Health News:Choices Recovery South Bend Discusses Addiction With Rising Hollywood Star Ben Stillwell 2Health News:Team Dental Clinic Unveils Plan to Drive Change in the Dental Tourism Industry 2Health News:Team Dental Clinic Unveils Plan to Drive Change in the Dental Tourism Industry 3Health News:Scottsdale Resident Named $12,000 Prize Winner- Arizona Central and KTVK 3TV Phoenix Partner in Mortgage Giveaway Contest 2Health News:LPGA’s Natalie Gulbis Raises an Additional $3,000 for the Boys & Girls Club of Atlantic City Through Horizon BCBSNJ’s Walking and Wellness Challenge 2Health News:TMG Health to Sponsor and Exhibit at AHIP’s Institute 2015 2
... PICK: Connexins: providing protection to cells destroyed in type ... lifelong disease characterized by high levels of sugar (glucose) ... immune system attacking and destroying the cells in their ... glucose levels. Surprisingly, little is known about the mechanisms ...
... Goodwin HealthDay Reporter , SUNDAY, Nov. 6 ... fresheners may evoke the holiday season for some. For ... runny, itchy noses and sneezing to asthma attacks. ... risen, so have complaints from their patients about reactions ...
... for the first time, they show significant decreases in crime, ... Researchers assessed more than 200 at-risk boys annually from ... crime, tobacco, alcohol, and marijuana use changed over time. While ... behavior, they had not isolated the additional effects of fatherhood. ...
... cells know what cell types to become? Why do cells ... develop into cancer cells? These are some of the questions ... research has a very strong position internationally and one of ... of Copenhagen. She has just received an ERC Starting Grant ...
... School of Medicine is honored to announce gifts to ... Research Foundation Professorship in Integrative Oncology. This professorship will ... as national leaders in teaching, research, and patient care ... gifts from The Parker Foundation and Helen Moss Cancer ...
... published research shows that more patients with end-stage ... hemodialysis as their initial kidney replacement therapy over ... the study now available in Arthritis Care ... College of Rheumatology (ACR), also found that African ...
Cached Medicine News:Health News:JCI online early table of contents: Nov. 7, 2011 2Health News:JCI online early table of contents: Nov. 7, 2011 3Health News:JCI online early table of contents: Nov. 7, 2011 4Health News:JCI online early table of contents: Nov. 7, 2011 5Health News:JCI online early table of contents: Nov. 7, 2011 6Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 2Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 3Health News:Fatherhood can help change a man's bad habits 2Health News:Research in cellular memory 2Health News:Pioneering professorship will teach innovative, patient-centered approach to cancer 2Health News:Pioneering professorship will teach innovative, patient-centered approach to cancer 3Health News:Most lupus nephritis patients with end-stage renal disease opt for hemodialysis therapy 2
(Date:6/2/2015)... , June 02, 2015 Research ... addition of the "Laboratory Centrifuges - Global ... Annual estimates and forecasts are provided ... seven-year historic analysis is provided for these markets. ... and secondary research. Company profiles are primarily based ...
(Date:6/2/2015)... June 02, 2015 Research and Markets ( http://www.researchandmarkets.com/research/g5r2nj/surgical_incision ... Closures - Global Strategic Business Report" report to their ... the US, Canada , Japan ... , Latin America , and Rest ... for Surgical Incision Closures in US$ Million by the following ...
(Date:6/2/2015)... 02, 2015 Research and Markets ( http://www.researchandmarkets.com/research/5tzcx6/specialty_enzymes ... Enzymes - Global Strategic Business Report" report to ... by the following End-Use Applications: Pharmaceutical & Diagnostics, Research/ ... for the US, Canada , ... Asia-Pacific , Latin America ...
Breaking Medicine Technology:Laboratory Centrifuges - Global Strategic Business Report 2014-2020: Developed Markets Slowdown, While Emerging Markets Surge 2Surgical Incision Closures - Global Strategic Business Report 2015 2Specialty Enzymes - Global Strategic Business Report 2015: Indispensable to the Pharmaceutical Industry 2
... CHICAGO--(BUSINESS WIRE)--Jun 23, 2007 - Late breaking ... 67th Annual,Scientific Sessions showed that, when used ... with,metformin provided significant glycemic improvement and was,generally ... with type 2,diabetes. Additional new data from ...
... BOSTON--(BUSINESS WIRE)--Jun 25, 2007 - HepaLife Technologies, ... announced that new,data presented at an international ... cell line outperforms,current cell technologies at replicating ... important step towards the production of,a cell-culture ...
Cached Medicine Technology:Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 2Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 3Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 4Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 5Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 6Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 7Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 8Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 9Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 10Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 11Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 12Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 13Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 14Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 15Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 16Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 17Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 18Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 19Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 20Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 21Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 22Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 23Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 24Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 25Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 26Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 27Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 28Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 29Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 30Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 31Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 32HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 2HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 3HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 4HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 5
Enzyme Immunoassay of Factor IX Antigen by ELISA Method, 96 tests....
Enzyme Immunoassay of -Thromboglobulin Antigen by ELISA Method, 96 tests....
Heparin-Platelet Factor 4 Induced Antibody...
Control Plasma for Assays of Unfractionated Heparins (UH) using Anti-Xa Methodon STA© Analyzers....
Medicine Products: